Dr David Yeung        Dr Devendra Hiwase     Dr Agnes Yong

Session 2: TKI resistance / failure

• When frontline therapy fails 
  (Dr David Yeung)
• CML - beyond chronic phase
  (Dr Devendra Hiwase)
• Allograft - still a role in CML?
  (Dr Agnes Yong)

When frontline therapy fails
Dr David Yeung- SA Pathology, University of Adelaide

• LASOR - failure to achieve 2009 ELN goals
• TIDEL II - failure to achieve optimal ELN 2013 treatment goals
• ENESTcmr - failure to achieve deep molecular response
• Ponatinib - drug of last resort?
• Asciminib (ABL001) - rising star?

CML - Beyond chronic phase?
Dr Devendra Hiwase - SA Pathology, University of Adelaide

• CML in accelerated phase (including patient case)
  • First-line IM in patients with newly diagnosed AP 
  • NIL following imatinib resistance or intolerance
  • DAS after imatinib failure
  • IM versus stem cell transplantation 
  • PON in patients with CML and PH+ ALL resistant/intolerant to IM
  • Treatment strategy recommendations for CML in AP
• CML in blast crisis (including patient case)
  • Survival of CML blast crisis patients
  • Prognostic factors and survival outcomes in patients with CML in blast crisis
  • Further treatment options

Allograft - Still a role in CML?
Dr Agnes Yong - SA Pathology, University of Adelaide

• Historic overview of allogeneic stem cell transplantation in CML
• Survival rates after transplantation
• EBMT score for alloSCT in CML?
• Which CML patient needs transplant?
• Which conditioning regime for alloSCT?
• Role of TKI's after transplant
• Summary